• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

远处转移的潜在机制——分子生物学

Underlying Mechanisms for Distant Metastasis - Molecular Biology.

作者信息

Pachmayr Eva, Treese Christoph, Stein Ulrike

机构信息

Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.

出版信息

Visc Med. 2017 Mar;33(1):11-20. doi: 10.1159/000454696. Epub 2017 Feb 9.

DOI:10.1159/000454696
PMID:28785563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5520302/
Abstract

BACKGROUND

The formation of distant metastases constitutes a complex process with a variety of different genes and pathways involved. To improve patient survival, it is necessary to understand the underlying mechanisms of metastasis to allow for targeted intervention.

METHODS

This review provides an overview of the general concepts of metastasis, focusing on the most important genes and pathways involved and on interventional strategies.

RESULTS

Cancer cells undergo different steps to form metastasis: most prominently, local invasion, intravasation, survival in the circulation, arrest at a distant organ site and extravasation, micrometastasis formation, and metastatic colonization. In order to pass these steps, different molecular pathways are of major importance: EGF/RAS/RAF/MEK/ERK, PI3K/Akt/mTOR, HGF/Met, Wnt/β-catenin, and VEGF signaling. The HGF/Met regulator MACC1 and the Wnt signaling target S100A4 have been shown to play a major role in the metastatic process. Each gene and pathway provides an opportunity for therapeutic intervention.

CONCLUSION

Since metastasis represents a highly limiting factor in cancer therapy causing 90% of cancer deaths, it is imperative to reveal the underlying mechanisms. This is fundamental for uncovering prognostic markers and new targeted therapy options.

摘要

背景

远处转移的形成是一个复杂的过程,涉及多种不同的基因和途径。为了提高患者生存率,有必要了解转移的潜在机制以便进行靶向干预。

方法

本综述概述了转移的一般概念,重点关注所涉及的最重要基因和途径以及干预策略。

结果

癌细胞经历不同步骤形成转移:最显著的是局部侵袭、血管内侵入、在循环中存活、在远处器官部位滞留和血管外渗、微转移形成以及转移灶定植。为了通过这些步骤,不同的分子途径至关重要:表皮生长因子/鼠肉瘤病毒癌基因/快速增殖纤维肉瘤/丝裂原活化蛋白激酶/细胞外信号调节激酶、磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白、肝细胞生长因子/间质上皮转化因子、Wnt/β-连环蛋白和血管内皮生长因子信号传导。肝细胞生长因子/间质上皮转化因子调节因子MACC1和Wnt信号传导靶点S100A4已被证明在转移过程中起主要作用。每个基因和途径都为治疗干预提供了机会。

结论

由于转移是癌症治疗中的一个高度限制因素,导致90%的癌症死亡,因此揭示其潜在机制势在必行。这对于发现预后标志物和新的靶向治疗选择至关重要。

相似文献

1
Underlying Mechanisms for Distant Metastasis - Molecular Biology.远处转移的潜在机制——分子生物学
Visc Med. 2017 Mar;33(1):11-20. doi: 10.1159/000454696. Epub 2017 Feb 9.
2
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.针对乳腺癌治疗中的 PI3K/AKT/mTOR 和 Raf/MEK/ERK 通路。
Cancer Treat Rev. 2013 Dec;39(8):935-46. doi: 10.1016/j.ctrv.2013.03.009. Epub 2013 May 3.
3
The potential therapeutic applications and prognostic significance of metastasis-associated in colon cancer-1 (MACC1) in cancers.结肠癌转移相关蛋白1(MACC1)在癌症中的潜在治疗应用及预后意义
Contemp Oncol (Pozn). 2016;20(4):273-80. doi: 10.5114/wo.2016.61846. Epub 2016 Sep 5.
4
Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.丹参酮 IIA 可通过双重阻断 Ras/Raf/MEK/ERK 和 PI3K/AKT/mTOR 通路抑制 MiaPaCa-2 人胰腺癌细胞。
Oncol Rep. 2018 Nov;40(5):3102-3111. doi: 10.3892/or.2018.6670. Epub 2018 Aug 23.
5
S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction.S100A4在癌症转移中的作用:Wnt信号驱动的转移限制干预措施。
Cancers (Basel). 2016 Jun 20;8(6):59. doi: 10.3390/cancers8060059.
6
MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis.miR-454-3p 通过调控 Wnt/β-catenin 信号通路抑制物促进乳腺癌转移。
Theranostics. 2019 Jan 1;9(2):449-465. doi: 10.7150/thno.29055. eCollection 2019.
7
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.PI3K/Akt/mTOR 和 Ras/Raf/MEK/ERK 信号通路抑制剂作为抗癌药物:结构和药理学视角。
Eur J Med Chem. 2016 Feb 15;109:314-41. doi: 10.1016/j.ejmech.2016.01.012. Epub 2016 Jan 12.
8
Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.针对转移相关基因及其通路的药物研发:癌症治疗的基本原理。
Biochim Biophys Acta. 2008 Dec;1786(2):87-104. doi: 10.1016/j.bbcan.2008.07.002. Epub 2008 Jul 22.
9
Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.芹菜素通过阻断PI3K/Akt信号通路和β4整合素功能抑制HGF促进的MDA-MB-231乳腺癌细胞侵袭性生长和转移。
Toxicol Appl Pharmacol. 2008 Jan 15;226(2):178-91. doi: 10.1016/j.taap.2007.09.013. Epub 2007 Sep 21.
10
[Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].[肿瘤学中RAS/RAF/MEK/ERK信号通路的未来靶向治疗:以黑色素瘤为例]
Bull Acad Natl Med. 2014 Feb;198(2):321-36; discussion 337-8.

引用本文的文献

1
ANKRD17 induces pro-survival signaling pathways that enhance cellular invasion and migration during hepatocellular carcinoma tumorigenesis.锚蛋白重复结构域17(ANKRD17)诱导促生存信号通路,在肝细胞癌发生过程中增强细胞侵袭和迁移能力。
iScience. 2025 Apr 17;28(5):112463. doi: 10.1016/j.isci.2025.112463. eCollection 2025 May 16.
2
Metformin and the PI3K/AKT signaling pathway: implications for cancer, cardiovascular, and central nervous system diseases.二甲双胍与PI3K/AKT信号通路:对癌症、心血管疾病和中枢神经系统疾病的影响
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1035-1055. doi: 10.1007/s00210-024-03358-3. Epub 2024 Sep 3.
3
The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib.丹诺瑞韦抑制胰腺腺癌细胞血管内皮生长因子的迁移和转移。
Turk J Gastroenterol. 2024 Feb;35(2):150-157. doi: 10.5152/tjg.2024.22319.
4
MACC1 Regulates LGR5 to Promote Cancer Stem Cell Properties in Colorectal Cancer.MACC1通过调控LGR5促进结直肠癌中癌症干细胞特性
Cancers (Basel). 2024 Jan 31;16(3):604. doi: 10.3390/cancers16030604.
5
Functional Enrichment Analysis of Tumor Microenvironment-Driven Molecular Alterations That Facilitate Epithelial-to-Mesenchymal Transition and Distant Metastasis.促进上皮-间质转化和远处转移的肿瘤微环境驱动分子改变的功能富集分析
Bioinform Biol Insights. 2024 Feb 4;18:11779322241227722. doi: 10.1177/11779322241227722. eCollection 2024.
6
CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis.CD4+ T 细胞来源的白细胞介素-22 通过促进血管生成增强肝转移。
Oncoimmunology. 2023 Oct 20;12(1):2269634. doi: 10.1080/2162402X.2023.2269634. eCollection 2023.
7
Differential response of MDA‑MB‑231 breast cancer and MCF10A normal breast cells to cytoskeletal disruption.MDA-MB-231 乳腺癌细胞和 MCF10A 正常乳腺细胞对细胞骨架破坏的差异反应。
Oncol Rep. 2023 Nov;50(5). doi: 10.3892/or.2023.8637. Epub 2023 Sep 29.
8
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression.p53 功能获得性突变通过 BRD4 依赖性 CSF-1 表达诱导转移。
Cancer Discov. 2023 Dec 12;13(12):2632-2651. doi: 10.1158/2159-8290.CD-23-0601.
9
SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer.SFPQ 及其同种型作为非小细胞肺癌的潜在生物标志物。
Int J Mol Sci. 2023 Aug 6;24(15):12500. doi: 10.3390/ijms241512500.
10
Targeting the metastatic niche: Single-cell lineage tracing in prime time.靶向转移小生境:黄金时期的单细胞谱系追踪
iScience. 2023 Feb 10;26(3):106174. doi: 10.1016/j.isci.2023.106174. eCollection 2023 Mar 17.

本文引用的文献

1
MicroRNA and Metastasis.微小 RNA 与转移。
Adv Cancer Res. 2016;132:165-207. doi: 10.1016/bs.acr.2016.07.004. Epub 2016 Aug 9.
2
Immune Regulation of the Metastatic Process: Implications for Therapy.转移过程的免疫调节:对治疗的启示。
Adv Cancer Res. 2016;132:139-63. doi: 10.1016/bs.acr.2016.05.004. Epub 2016 Jun 17.
3
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.一项关于FOLFOX联合或不联合MET抑制剂奥那珠单抗治疗晚期胃及胃食管交界腺癌的随机II期研究。
Oncologist. 2016 Sep;21(9):1085-90. doi: 10.1634/theoncologist.2016-0038. Epub 2016 Jul 8.
4
Cancer Tills the Premetastatic Field: Mechanistic Basis and Clinical Implications.癌症塑造前转移微环境:机制基础与临床意义
Clin Cancer Res. 2016 Aug 1;22(15):3725-33. doi: 10.1158/1078-0432.CCR-16-0028. Epub 2016 Jun 1.
5
Tumor refractoriness to anti-VEGF therapy.肿瘤对抗血管生成素治疗的难治性。
Oncotarget. 2016 Jul 19;7(29):46668-46677. doi: 10.18632/oncotarget.8694.
6
Tumor cell intravasation.肿瘤细胞内渗
Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C1-C14. doi: 10.1152/ajpcell.00238.2015. Epub 2016 Apr 13.
7
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT.通过自分泌抑制WNT实现转移潜伏期和免疫逃逸
Cell. 2016 Mar 24;165(1):45-60. doi: 10.1016/j.cell.2016.02.025.
8
Biomarker development in MET-targeted therapy.MET靶向治疗中的生物标志物开发。
Oncotarget. 2016 Jun 14;7(24):37370-37389. doi: 10.18632/oncotarget.8276.
9
MACC1 Induces Tumor Progression in Transgenic Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4.MACC1 通过增加多能性标志物 Nanog 和 Oct4 诱导转基因小鼠和结直肠癌患者的肿瘤进展。
Clin Cancer Res. 2016 Jun 1;22(11):2812-24. doi: 10.1158/1078-0432.CCR-15-1425. Epub 2016 Jan 12.
10
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.MEK抑制剂及其在晚期黑色素瘤治疗中的潜力:联合治疗的优势
Drug Des Devel Ther. 2015 Dec 21;10:43-52. doi: 10.2147/DDDT.S93545. eCollection 2016.